Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Citrox Biosciences Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to a distinct examiner and is located within 1 distinct art unit. BERRY, LAYLA D is the busiest examiner for this portfolio, as they are responsible for the 1 pending office action currently active.
The concentration of the portfolio into a single art unit and a single examiner means that the current prosecution success in Biotechnology & Pharmaceuticals is tied to a single point of review. BERRY, LAYLA D manages the entirety of the current workload at the office. Practitioners should focus on the specific examiner's history, as there are no other active matters to provide a baseline for comparison within this portfolio.
With only a single pending matter, the administrative burden is low, but the strategic importance of the assigned individual is high. The 1 distinct art unit involved will dictate the procedural norms for this case. Because the busiest examiner is the only one mentioned, their individual tendencies will be the primary factor in the prosecution of the current application in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287376 | NUTRITIONAL SUPPLEMENTS FOR AMELIORATION OF RESPIRATORY TRACT INFECTIONS | BERRY, LAYLA D | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287376 | NUTRITIONAL SUPPLEMENTS FOR AMELIORATION OF RESPIRATORY TRACT INFECTIONS | BERRY, LAYLA D | 1693 | §102§103§112 | Non-Final OA | — | Pending | Oct 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial